Compare
V2X, Inc. vs Genpact Ltd vs FTI Consulting, Inc vs Astrana Health, Inc.
| Latest fiscal year | V2X, Inc. VVX | Genpact Ltd G | FTI Consulting, Inc FCN | Astrana Health, Inc. ASTH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.48B | $5.08B | $3.79B | $3.18B |
| Revenue growth (YoY) | +3.7% | +6.6% | +2.4% | +56.4% |
| Gross margin | 8.3% (computed) | 36.0% | 32.1% | n/a |
| Operating margin | 4.3% | 14.8% | 10.3% | 2.5% |
| Net margin | 1.7% | 10.9% | 7.1% | 0.7% |
| Net income | $77.88M | $552.49M | $270.87M | $22.49M |
| EPS (Diluted) | $2.45 | $3.13 | $8.24 | $0.46 |
| Operating cash flow | $181.99M | $812.86M | $152.13M | $114.60M |
| Free cash flow | $170.07M | $734.65M | $93.60M | $104.49M |
| Cash & equivalents | n/a | $853.84M | $265.09M | $429.47M |
| Total assets | $3.28B | $5.84B | $3.49B | $2.22B |
| Total liabilities | $2.20B | $3.29B | $1.76B | $1.66B |
| Shareholders' equity | $1.08B | $2.55B | $1.73B | $779.29M |
| Return on year-end equity | 7.2% | 21.7% | 15.6% | 2.9% |
| Shares outstanding | 31.17M | 170.34M | 30.86M | 48.89M |
Revenue, most recent five fiscal years
| Fiscal year | V2X, Inc. | Genpact Ltd | FTI Consulting, Inc | Astrana Health, Inc. |
|---|---|---|---|---|
| Latest | $4.48B Ended 2025-12-31 | $5.08B Ended 2025-12-31 | $3.79B Ended 2025-12-31 | $3.18B Ended 2025-12-31 |
| 1 year earlier | $4.32B Ended 2024-12-31 | $4.77B Ended 2024-12-31 | $3.70B Ended 2024-12-31 | $2.03B Ended 2024-12-31 |
| 2 years earlier | $3.96B Ended 2023-12-31 | $4.48B Ended 2023-12-31 | $3.49B Ended 2023-12-31 | $1.39B Ended 2023-12-31 |
| 3 years earlier | $2.89B Ended 2022-12-31 | $4.37B Ended 2022-12-31 | $3.03B Ended 2022-12-31 | $1.14B Ended 2022-12-31 |
| 4 years earlier | $1.78B Ended 2021-12-31 | $4.02B Ended 2021-12-31 | $2.78B Ended 2021-12-31 | $773.91M Ended 2021-12-31 |